NO904712D0 - Nanbh diagnostiske midler og vaksiner. - Google Patents

Nanbh diagnostiske midler og vaksiner.

Info

Publication number
NO904712D0
NO904712D0 NO1990904712A NO904712A NO904712D0 NO 904712 D0 NO904712 D0 NO 904712D0 NO 1990904712 A NO1990904712 A NO 1990904712A NO 904712 A NO904712 A NO 904712A NO 904712 D0 NO904712 D0 NO 904712D0
Authority
NO
Norway
Prior art keywords
hcv
genome
nanbh
vaccines
polyprotein
Prior art date
Application number
NO1990904712A
Other languages
English (en)
Other versions
NO303941B1 (no
NO904712L (no
Inventor
Michael Houghton
Qui-Lim Choo
George Kuo
Original Assignee
Chiron Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27406397&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO904712(D0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Chiron Corp filed Critical Chiron Corp
Publication of NO904712D0 publication Critical patent/NO904712D0/no
Publication of NO904712L publication Critical patent/NO904712L/no
Priority to NO960741A priority Critical patent/NO304656B1/no
Priority to NO960741A priority patent/NO304654B1/no
Publication of NO303941B1 publication Critical patent/NO303941B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C12Q1/701—Specific hybridization probes
    • C12Q1/706—Specific hybridization probes for hepatitis
    • C12Q1/707—Specific hybridization probes for hepatitis non-A, non-B Hepatitis, excluding hepatitis D
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1081—Togaviridae, e.g. flavivirus, rubella virus, hog cholera virus
    • C07K16/109—Hepatitis C virus; Hepatitis G virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844—Nucleic acid amplification reactions
    • C12Q1/6853—Nucleic acid amplification reactions using modified primers or templates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844—Nucleic acid amplification reactions
    • C12Q1/6858—Allele-specific amplification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C12Q1/701—Specific hybridization probes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • Analytical Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Plant Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
NO904712A 1989-03-17 1990-10-30 Vesentlig isolert polypeptid for anvendelse ved detektering av antistoff mot HCV in vitro og i en in vitro immuno analyse, immunoanalysett og antistoff sammensetning NO303941B1 (no)

Priority Applications (2)

Application Number Priority Date Filing Date Title
NO960741A NO304656B1 (no) 1989-03-17 1996-02-23 Polynukleotid i vesentlig isolert form, analysesett, polymerase kjedereaksj
NO960741A NO304654B1 (no) 1989-03-17 1996-02-23 Fremgangsmaate for fremstilling av et terapeutisk aktivt polypeptid, rekombinant vektor og vertscelle

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US32533889A 1989-03-17 1989-03-17
US34133489A 1989-04-20 1989-04-20
US35500289A 1989-05-18 1989-05-18
PCT/US1990/001348 WO1990011089A1 (en) 1989-03-17 1990-03-15 Nanbv diagnostics and vaccines

Publications (3)

Publication Number Publication Date
NO904712D0 true NO904712D0 (no) 1990-10-30
NO904712L NO904712L (no) 1990-10-30
NO303941B1 NO303941B1 (no) 1998-09-28

Family

ID=27406397

Family Applications (1)

Application Number Title Priority Date Filing Date
NO904712A NO303941B1 (no) 1989-03-17 1990-10-30 Vesentlig isolert polypeptid for anvendelse ved detektering av antistoff mot HCV in vitro og i en in vitro immuno analyse, immunoanalysett og antistoff sammensetning

Country Status (19)

Country Link
EP (3) EP1394255A3 (no)
JP (13) JP2656995B2 (no)
KR (2) KR0185373B1 (no)
AT (1) ATE286979T1 (no)
AU (3) AU666766B2 (no)
CA (1) CA2012482C (no)
DE (3) DE69034182T2 (no)
DK (1) DK0388232T3 (no)
ES (2) ES2228297T1 (no)
FI (3) FI106211B (no)
GR (1) GR910300016T1 (no)
HU (3) HU225068B1 (no)
IE (2) IE20060607A1 (no)
IL (1) IL93764A (no)
MY (1) MY110260A (no)
NO (1) NO303941B1 (no)
PT (1) PT93480B (no)
UA (1) UA50829C2 (no)
WO (1) WO1990011089A1 (no)

Families Citing this family (181)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5523215A (en) * 1985-03-28 1996-06-04 Chiron Corporation Enhanced purification and expression of insoluble recombinant proteins
US6171782B1 (en) 1987-11-18 2001-01-09 Chiron Corporation Antibody compositions to HCV and uses thereof
US5714596A (en) * 1987-11-18 1998-02-03 Chiron Corporation NANBV diagnostics: polynucleotides useful for screening for hepatitis C virus
US6861212B1 (en) 1987-11-18 2005-03-01 Chiron Corporation NANBV diagnostics and vaccines
US5712088A (en) * 1987-11-18 1998-01-27 Chiron Corporation Methods for detecting Hepatitis C virus using polynucleotides specific for same
US5350671A (en) * 1987-11-18 1994-09-27 Chiron Corporation HCV immunoassays employing C domain antigens
US5698390A (en) * 1987-11-18 1997-12-16 Chiron Corporation Hepatitis C immunoassays
HU225068B1 (en) * 1989-03-17 2006-05-29 Chiron Corp Process for producing diagnostics and vaccine of nanbh
US6027729A (en) * 1989-04-20 2000-02-22 Chiron Corporation NANBV Diagnostics and vaccines
GEP20002164B (en) * 1989-05-18 2000-07-10 Novartis Vaccines & Diagnostic Oligomers, method for detecting of hcv sequence, kit for its detecting, method for production of the blood free from hcv
EP0416725A3 (en) * 1989-07-14 1991-03-20 Chugai Seiyaku Kabushiki Kaisha Blood-borne non-a, non-b hepatitis specific protein, dna encoding it, and process for its production
CA2065287C (en) * 1989-09-15 1999-12-21 Tatsuo Miyamura New hcv isolates
US5372928A (en) * 1989-09-15 1994-12-13 Chiron Corporation Hepatitis C virus isolates
US7166287B1 (en) 1989-12-18 2007-01-23 Glaxo Wellcome Inc. Viral agent
CH684594A5 (fr) * 1989-12-18 1994-10-31 Wellcome Found Agent viral.
CA2032907C (en) * 1989-12-22 2002-05-14 Richard R. Lesniewski Hepatitis c assay
US5308750A (en) * 1989-12-22 1994-05-03 Abbott Laboratories Monoclonal antibodies to putative HCV E2/NS1 proteins and methods for using same
EP0435229A1 (en) * 1989-12-27 1991-07-03 Sanwa Kagaku Kenkyusho Co., Ltd. DNA of non-A, non-B hepatitis virus gene, its clone and use thereof
US5747239A (en) * 1990-02-16 1998-05-05 United Biomedical, Inc. Synthetic peptides specific for the detection of antibodies to HCV, diagnosis of HCV infection and preventions thereof as vaccines
US5106726A (en) * 1990-02-16 1992-04-21 United Biomedical, Inc. Synthetic peptides specific for the detection of antibodies to HCV
KR940000755B1 (ko) * 1990-02-16 1994-01-29 유나이티드 바이오메디칼 인코오포레이티드 Hcv에 대한 항체 검출, hcv 감염의 진단 및 백신으로서의 그 예방에 특히 적합한 합성 펩티드
US5582968A (en) * 1990-02-16 1996-12-10 United Biomedical, Inc. Branched hybrid and cluster peptides effective in diagnosing and detecting non-A, non-B hepatitis
DE69133617D1 (de) * 1990-04-04 2009-07-23 Novartis Vaccines & Diagnostic Protease von Hepatitis C Virus
WO1991015771A1 (en) † 1990-04-04 1991-10-17 Chiron Corporation Combinations of hepatitis c virus (hcv) antigens for use in immunoassays for anti-hcv antibodies
IE911130A1 (en) * 1990-04-04 1991-10-09 Protos Hepatitis c protease inhibitors
CA2079912C (en) * 1990-04-06 2000-07-11 Gregory Reyes Hepatitis c virus epitopes
JP3050395B2 (ja) * 1990-06-12 2000-06-12 国立感染症研究所長 Ｃ型肝炎ウイルス抗原ポリペプチド、その産生方法および抗体の検出方法
CA2044296A1 (en) * 1990-06-12 1991-12-13 Hiroaki Okamoto Oligonucleotide primers, and their application for high-fidelity detection of non-a, non-b hepatitis virus
US5747339A (en) * 1990-06-25 1998-05-05 Research Foundation For Microbial Diseases Of Osaka Non-A, non-B hepatitis virus genomic CDNA and antigen polypeptide
CA2045326A1 (en) * 1990-06-25 1991-12-26 Hiroto Okayama Non-a, non-b, hepatitis virus particles
EP0933426A1 (en) * 1990-06-25 1999-08-04 The Research Foundation for Microbial Diseases of Osaka University Non-a, non-b hepatitis virus genomic cdna fragments and antigen polypeptides
ATE115964T1 (de) * 1990-06-30 1995-01-15 Akzo Nobel Nv Non-a non-b sequenzen.
EP0468657A3 (en) * 1990-07-09 1992-02-05 Tonen Corporation Non-a non b hepatitis-specific antigen and its use in hepatitus diagnosis
ES2100185T3 (es) * 1990-07-11 1997-06-16 Shionogi & Co Secuencia de adnc y deteccion del virus de la hepatitis c.
CA2047792C (en) * 1990-07-26 2002-07-02 Chang Y. Wang Synthetic peptides specific for the detection of antibodies to hcv, diagnosis of hcv infection and prevention thereof as vaccines
AU660940B2 (en) * 1990-08-10 1995-07-13 Novartis Vaccines And Diagnostics, Inc. NANBV diagnostics: polynucleotides useful for screening for hepatitis C virus
JP3114731B2 (ja) * 1990-08-14 2000-12-04 国立感染症研究所長 Ｃ型肝炎ウイルス抗体検出用ペプチド抗原及びその使用方法
CA2049679C (en) * 1990-08-24 2005-06-21 Sushil G. Devare Hepatitis c assay utilizing recombinant antigens
US6172189B1 (en) * 1990-08-24 2001-01-09 Abbott Laboratories Hepatitis C assay utilizing recombinant antigens
US7863008B2 (en) 1990-08-25 2011-01-04 Bioprocess Pty Ltd. Method for detecting NANBV associated seroconversion
ES2273934T5 (es) * 1990-08-25 2011-05-17 Bioprocess Pty Ltd Antígeno del virus de la hepatitis no a, no b, métodos diagnósticos y vacunas.
DK0479376T3 (da) * 1990-10-05 1995-05-15 Akzo Nobel Nv Peptider, der er immunokemisk reaktive antistoffer rettet mod hepatitis Non-A, Non-B virus
EP0484787B1 (de) * 1990-11-03 2001-10-10 Dade Behring Marburg GmbH HCV-spezifische Peptide, Mittel dazu und ihre Verwendung
US5753430A (en) * 1990-11-07 1998-05-19 Abbott Laboratories Monoclonal antibodies to hepatitis C virus and method for using same
CA2095735C (en) * 1990-11-07 2004-02-03 Smriti U. Mehta Monoclonal antibodies to hepatitis c virus and method for using same
CA2055149A1 (en) * 1990-11-08 1992-05-09 Hiroaki Okamoto Non-a, non-b hepatitis virus related antigen, antibody, detection systems, polynucleotides and polypeptides
DK1471073T3 (da) * 1990-11-08 2009-01-26 Novartis Vaccines & Diagnostic Hepatitis C-virus-asialoglycoproteiner
US6274148B1 (en) 1990-11-08 2001-08-14 Chiron Corporation Hepatitis C virus asialoglycoproteins
JP2945759B2 (ja) 1990-11-08 1999-09-06 カイロン コーポレイション Ｃ型肝炎ウイルスアシアロ糖タンパク質
RO115446B1 (ro) * 1990-11-08 2000-02-28 Chiron Corp Procedeu de obtinere a asialoglicoproteinelor purificate provenind de la virusul hepatitei c
WO1992009634A1 (en) * 1990-11-29 1992-06-11 Toray Industries, Incorporated Non-a non-b hepatitis virus antigen protein
EP0488812B1 (en) * 1990-11-30 1999-06-09 Immuno Japan Inc. Non-A, non-B hepatitis related nucleic acids, antigens, antibodies and their detection reagents
DK0489968T3 (da) * 1990-12-14 1997-03-24 Innogenetics Nv Syntetiske antigener til påvisning af antistoffer imod hepatitis C virus
US6007982A (en) * 1990-12-14 1999-12-28 Innogenetics N.V. Synthetic antigens for the detection of antibodies to hepatitis C virus
US5910404A (en) 1990-12-14 1999-06-08 Innogenetics N.V. Synthetic antigens for the detection of antibodies to hepatitis C virus
DE4041304A1 (de) * 1990-12-21 1992-06-25 Mikrogen Molekularbiol Entw Von strukturproteinen des hepatitis c-virus abgeleitete polypeptide, testkits, die diese polypeptide enthalten und impfstoffe gegen infektionen von hepatitis c-viren
EP0569537B1 (en) * 1991-01-31 1998-06-17 Abbott Laboratories Monoclonal antibodies to putative hcv envelope region and methods for using same
DK0501557T3 (da) * 1991-03-01 1995-04-10 Akzo Nobel Nv Peptider, der er immunokemisk reaktive med antistoffer rettet mod hepatitis non-A, non-B-virus
EP0532746B1 (en) * 1991-03-26 1997-01-02 Dade International Inc. Assay for non-a non-b hepatitis
US5574132A (en) * 1991-04-05 1996-11-12 Biochem Immunosystems Inc. Peptides and mixtures thereof for detecting antibodies to hepatitis C virus (HCV)
EP0510952A1 (en) * 1991-04-26 1992-10-28 Immuno Japan Inc. Oligonucleotide primers and their application for high-fidelity detection of non-a, non-b hepatitis virus
PL169880B1 (pl) * 1991-05-08 1996-09-30 Chiron Corp Sposób wytwarzania produktu hybrydyzacji z kwasem nukleinowym wirusa zapalenia watroby C PL PL PL
US6190864B1 (en) 1991-05-08 2001-02-20 Chiron Corporation HCV genomic sequences for diagnostics and therapeutics
FR2677372B1 (fr) * 1991-06-06 1994-11-10 Pasteur Institut Sequences nucleotidiques et peptidiques d'un isolat de virus de l'hepatite c, applications diagnostiques et therapeutiques.
WO1992022655A1 (en) 1991-06-10 1992-12-23 Lucky Limited Hepatitis c diagnostics and vaccines
CA2070952A1 (en) * 1991-06-11 1992-12-12 Makoto Seki Gene of hepatitis c virus or fragment thereof, polypeptide encoded by the same
WO1992022571A1 (en) * 1991-06-13 1992-12-23 Baxter Diagnostics Inc. Immunoassay for non-a non-b hepatitis
ES2188583T3 (es) * 1991-06-24 2003-07-01 Chiron Corp Polipeptidos para el virus de la hepatitis c (hcv).
IT1249684B (it) * 1991-07-19 1995-03-09 Sorin Biomedica Spa Epitopi della proteina env del virus dell'epatite c.
IT1249685B (it) * 1991-07-19 1995-03-09 Sorin Biomedica Spa Medoto per la rivelazione di anticorpi contro il virus dell'epatite c e corredi per la sua realizzazione
CA2115926A1 (en) * 1991-08-21 1993-03-04 Stephen H. Dailey Hepatitis c assay utilizing recombinant antigens to ns1
DK0599913T3 (da) * 1991-08-21 1999-08-16 Abbott Lab Monoklonale antistoffer mod formodet hepatitis C-virus NS5-proteiner og anvendelsesmetoder af samme
WO1993004087A1 (en) * 1991-08-21 1993-03-04 Abbott Laboratories Hepatitis c assay utilizing recombinant antigens to c-100 region
WO1993004089A1 (en) * 1991-08-21 1993-03-04 Abbott Laboratories Hepatitis c assay utilizing recombinant antigens from ns5 region
DE69223562T2 (de) * 1991-08-27 1998-06-04 Hoffmann La Roche Verfahren und Reagenzien zum Nachweis von Hepatitis C
US5427909A (en) * 1991-09-09 1995-06-27 Immuno Japan Inc. Oligonucleotides and determination system of HCV genotypes
PL171489B1 (pl) * 1991-09-13 1997-05-30 Chiron Corp Sposób wytwarzania kompozycji immunogenicznej reagujacej immunologicznie krzyzowo z wieloma izolatami HCV PL
AU2683792A (en) * 1991-09-16 1993-04-27 Genelabs Technologies, Inc. Peptide based hepatitis c virus immunoassays
WO1993006247A1 (en) † 1991-09-16 1993-04-01 Abbott Laboratories Hepatitis c assay
ZA927243B (en) * 1991-10-07 1994-01-26 Akzo Nv Non-A, Non-B peptides
JP3158177B2 (ja) * 1991-10-08 2001-04-23 国立感染症研究所長 Ｃ型肝炎診断薬
ZA927837B (en) * 1991-10-15 1994-03-11 Akzo Nv Monoclonal antibodiesto hepatitis C virus
EP0573624A4 (en) * 1991-11-07 1997-09-17 Baxter Diagnostics Inc Epitope mapping ot the c33c region of hcv
JP3688290B2 (ja) 1991-11-21 2005-08-24 コモン サーヴィシス エージェンシー Ｃ型肝炎ウイルス検査
WO1993011158A2 (en) * 1991-12-06 1993-06-10 Akzo Nobel N.V. Non-a, non-b peptides
US5811246A (en) * 1991-12-17 1998-09-22 The Research Foundation Of State University Of New York Process for immobilization onto the surfaces of ELISA plates of a compound carrier complex and for immunization
WO1993015193A1 (en) * 1992-01-31 1993-08-05 Abbott Laboratories Mammalian expression systems for hcv proteins
US6709828B1 (en) 1992-03-06 2004-03-23 N.V. Innogenetics S.A. Process for the determination of peptides corresponding to immunologically important epitopes and their use in a process for determination of antibodies or biotinylated peptides corresponding to immunologically important epitopes, a process for preparing them and compositions containing them
DK0891982T3 (da) * 1992-03-06 2007-09-03 Innogenetics Nv HIV-peptider
US6667387B1 (en) 1996-09-30 2003-12-23 N.V. Innogenetics S.A. HCV core peptides
US5866139A (en) * 1992-06-04 1999-02-02 Institut Pasteur Nucleotide and peptide sequences of a hepatitis C virus isolate, diagnostic and therapeutic applications
JPH05344899A (ja) * 1992-06-11 1993-12-27 Kokuritsu Yobou Eisei Kenkyusho Ｃ型肝炎ウイルス外被タンパク質の産生法
UA39944C2 (uk) 1992-07-07 2001-07-16 Чірон Корпорейшн Спосіб визначення ранньої сероконверсії у ссавця-хазяїна до вірусу гепатиту с і набір для використання в способі
DE69334323D1 (de) 1992-07-16 2010-05-06 Advanced Life Science Inst Inc Antigenetische Peptide für die Gruppierung des Hepatitis C Virus sowie Reagenzien und Verfahren dafür
DE4240980A1 (de) * 1992-08-07 1994-02-10 Boehringer Mannheim Gmbh HCV Peptidantigene und Verfahren zur Bestimmung von HCV
JPH06311885A (ja) * 1992-08-25 1994-11-08 Mitsubishi Kasei Corp Ｃ型肝炎ウイルス遺伝子に相補的なアンチセンス化合物
JPH08506479A (ja) * 1992-09-10 1996-07-16 財団法人化学及血清療法研究所 Ｃ型肝炎ウイルス関連疾患の治療のための組成物および方法
US6423489B1 (en) * 1992-09-10 2002-07-23 Isis Pharmaceuticals, Inc. Compositions and methods for treatment of Hepatitis C virus-associated diseases
US5922857A (en) * 1992-09-28 1999-07-13 Chiron Corporation Methods and compositions for controlling translation of HCV proteins
ATE310817T1 (de) * 1992-09-28 2005-12-15 Chiron Corp Verfahren und zusammensetzungen zur kontrolle der übersetzung der hcv-proteine
AU5142393A (en) * 1992-09-29 1994-04-26 Cedars-Sinai Medical Center One step rna and combined one step rna and dna polymerase chain reaction for detection of rare rna or rna and dna
US6153378A (en) * 1992-10-16 2000-11-28 Bionova Corporation Diagnosis of, and vaccination against, a positive stranded RNA virus using an isolated, unprocessed polypeptide encoded by a substantially complete genome of such virus
JPH06153959A (ja) * 1992-10-16 1994-06-03 Evernew Biotec Inc Ｃ型肝炎ウィルスの非構造タンパク質及びそれを用いての診断方法及びキット
JP2778886B2 (ja) * 1992-10-16 1998-07-23 エバーニュー バイオテック インコーポレイティド Ｃ型肝炎ウィルスのコア抗原タンパク質及びそれを用いての診断方法及びキット
AU6769594A (en) * 1993-04-22 1994-11-08 Genelabs Technologies, Inc. Hepatitis c virus immunodiagnostic antigens and antibodies
JP3645904B2 (ja) * 1993-05-10 2005-05-11 カイロン コーポレイション Ｃ型肝炎ウイルスの型の分類方法およびそこで使用する試薬
WO1994026306A1 (en) 1993-05-12 1994-11-24 Chiron Corporation Conserved motif of hepatitis c virus e2/ns1 region
US5610009A (en) * 1994-01-28 1997-03-11 Abbott Laboratories Mammalian expression systems for hepatitis C virus envelope genes
US5709995A (en) 1994-03-17 1998-01-20 The Scripps Research Institute Hepatitis C virus-derived peptides capable of inducing cytotoxic T lymphocyte responses
WO1995030902A1 (en) * 1994-05-09 1995-11-16 Abbott Laboratories Method and reagents useful for improving immunoassay specificity
US6511812B1 (en) 1994-05-09 2003-01-28 Abbott Laboratories Method and test kit for use in improving immunoassay specificity
EP0759979A4 (en) * 1994-05-10 1999-10-20 Gen Hospital Corp ANTISENSE OLIGONUCLEOTIDES INHIBITION OF HEPATITIS C VIRUS
JP3217600B2 (ja) 1994-07-12 2001-10-09 株式会社先端生命科学研究所 非ａ非ｂ型肝炎ウイルス関連抗原のイムノアッセイ、それに使用するモノクローナル抗体、およびこの抗体を産生するハイブリドーマ
DE69535899D1 (de) 1994-07-29 2009-01-22 Novartis Vaccines & Diagnostic Hepatitis C E2 verkuerzte Polypeptid sowie Verfahen zu seiner Herstellung
DK0721505T4 (da) 1994-07-29 2006-08-14 Innogenetics Nv Rensede hepatitis C-virus-kappeproteiner til diagnostisk og terapeutisk anvendelse
WO1996004301A2 (en) * 1994-07-29 1996-02-15 Chiron Corporation Novel hepatitis c e1 and e2 truncated polypeptides and methods of obtaining the same
DE4428705A1 (de) * 1994-08-12 1996-02-15 Boehringer Mannheim Gmbh Rekombinantes Antigen aus der NS3-Region des Hepatitis C Virus
US6235888B1 (en) * 1994-10-05 2001-05-22 The General Hospital Corporation Hepatitis C virus vaccine
JPH10507643A (ja) 1994-10-21 1998-07-28 イノジェネティックス・ナムローゼ・フェンノートシャップ Ｃ型肝炎ウイルス遺伝子型の新規配列、ならびにそれらの予防薬、治療薬および診断薬としての使用
ES2168456T3 (es) * 1995-01-16 2002-06-16 North Sydney Area Health Serv Peptidos que afectan a los linfocitos t.
KR970010787A (ko) * 1995-08-14 1997-03-27 성재갑 B형 간염 바이러스 표면항원과 c형 간염 바이러스 외피 단백질의 융합 단백질 및 이를 포함하는 혼합 백신
US6127116A (en) * 1995-08-29 2000-10-03 Washington University Functional DNA clone for hepatitis C virus (HCV) and uses thereof
GB9517926D0 (en) 1995-09-01 1995-11-01 Biocine Spa Binding protein
US5837442A (en) 1995-11-29 1998-11-17 Roche Molecular Systems, Inc. Oligonucleotide primers for amplifying HCV nucleic acid
US5851759A (en) * 1996-04-19 1998-12-22 Chiron Corporation Heteroduplex tracking assay (HTA) for genotyping HCV
IT1284635B1 (it) * 1996-04-24 1998-05-21 Clonit Spa Metodo per la rivelazione di acidi nucleici amplificati e kit per il suo uso.
JP3715027B2 (ja) 1996-05-07 2005-11-09 シスメックス株式会社 Ｃ型肝炎ウイルス感染症診断薬
US7338759B1 (en) 1997-03-04 2008-03-04 Washington University HCV variants
US7049428B1 (en) 1998-03-04 2006-05-23 Washington University HCV variants
FR2760458B1 (fr) * 1997-03-05 1999-04-23 Bio Merieux Peptide structural antigenique, composes antigenique et immunogene et utilisations dans la detection, la prevention et le traitement d'une infection par le vhc
EP0980434B1 (en) 1997-05-06 2009-07-29 Novartis Vaccines and Diagnostics, Inc. Intracellular production of hepatitis c e2 truncated polypeptid
DE69841322D1 (de) 1997-10-06 2010-01-07 Novartis Vaccines & Diagnostic Hepatitis c rezeptorprotein cd81
JP2002537102A (ja) 1999-02-26 2002-11-05 カイロン コーポレイション 吸着された高分子および微粒子を有するミクロエマルジョン
WO2000050078A1 (en) 1999-02-26 2000-08-31 Chiron Corporation Use of bioadhesives and adjuvants for the mucosal delivery of antigens
US7196066B1 (en) 1999-11-03 2007-03-27 Powderject Vaccines, Inc. DNA-vaccines based on constructs derived from the genomes of human and animal pathogens
GB9927320D0 (en) * 1999-11-18 2000-01-12 Chiron Spa Exosome separation
CN1214244C (zh) 2000-06-15 2005-08-10 希龙公司 免疫测定固相支持物、其试剂盒 、制备以及用途
EP1178116A1 (en) * 2000-08-03 2002-02-06 Hybrigenics S.A. Sid nucleic acids and polypeptides selected from a pathogenic strain of hepatitis C virus and applications thereof
US7022830B2 (en) 2000-08-17 2006-04-04 Tripep Ab Hepatitis C virus codon optimized non-structural NS3/4A fusion gene
US6680059B2 (en) 2000-08-29 2004-01-20 Tripep Ab Vaccines containing ribavirin and methods of use thereof
JP5175417B2 (ja) 2000-08-17 2013-04-03 トリペップ アクチ ボラゲット リバビリンを含むワクチンおよびその使用方法
RU2286172C2 (ru) 2000-08-17 2006-10-27 Трипеп Аб Вакцины, содержащие рибавирин, и способы их использования
ES2345876T3 (es) 2001-05-31 2010-10-05 Novartis Vaccines And Diagnostics, Inc. Particulas de replicones de alfavirus quimericos.
US7196183B2 (en) 2001-08-31 2007-03-27 Innogenetics N.V. Hepatitis C virus genotype, and its use as prophylactic, therapeutic and diagnostic agent
AR045702A1 (es) 2001-10-03 2005-11-09 Chiron Corp Composiciones de adyuvantes.
US7049060B2 (en) 2001-11-05 2006-05-23 Ortho-Clinical Diagnostics, Inc. HCV anti-core monoclonal antibodies
EP1531796B1 (en) 2002-02-20 2016-09-28 GlaxoSmithKline Biologicals SA Microparticles with adsorbed polypeptide-containing molecules
US7598421B2 (en) 2002-05-08 2009-10-06 Ucl Biomedica Plc Materials for the delivery of biologically-active material to cells
FR2839555B1 (fr) 2002-05-10 2007-07-27 Bio Rad Pasteur Procede de detection simultanee d'un antigene et d'un anticorps d'un microorganisme infectieux
FR2839722A1 (fr) 2002-05-17 2003-11-21 Bio Merieux Nouvelles compositions peptidiques et leur utilisation notamment dans la preparation de compositions pharmaceutiques actives contre le virus de l'hepatite c
US7166426B2 (en) 2002-09-09 2007-01-23 Novartis Vaccines And Diagnostics, Inc. HCV assay
WO2004036190A2 (en) 2002-10-16 2004-04-29 Gen-Probe Incorporated Compositions and methods for detecting west nile virus
US7927840B2 (en) 2006-09-11 2011-04-19 Gen Probe Incorporated Method for detecting West Nile Virus nucleic acids in the 3′ non-coding region
CA2511512C (en) 2002-12-27 2013-10-29 Chiron Corporation Immunogenic compositions containing phospholipid
US7695725B2 (en) 2003-02-06 2010-04-13 Aduro Biotech Modified free-living microbes, vaccine compositions and methods of use thereof
KR101192652B1 (ko) 2003-02-06 2012-10-19 앤저 테라퓨틱스 인코퍼레이티드 비포식 세포로의 침투가 약화된 리스테리아, 리스테리아를 포함하는 백신, 및 그것의 사용방법
US7833775B2 (en) 2003-02-06 2010-11-16 Aduro Biotech Modified free-living microbes, vaccine compositions and methods of use thereof
US7731967B2 (en) 2003-04-30 2010-06-08 Novartis Vaccines And Diagnostics, Inc. Compositions for inducing immune responses
ES2596753T3 (es) 2003-08-29 2017-01-11 Fujirebio Europe N.V. Nuevo clado del virus de la hepatitis C y secuencias prototipo del mismo
WO2006070028A1 (es) * 2004-12-23 2006-07-06 Berthet Francois Xavier Composiciones y procedimientos para detectar infección patógena
US7842289B2 (en) 2003-12-24 2010-11-30 Aduro Biotech Recombinant nucleic acid molecules, expression cassettes, and bacteria, and methods of use thereof
JP2008508320A (ja) 2004-07-29 2008-03-21 カイロン コーポレイション Ｓｔｒｅｐｔｏｃｏｃｃｕｓａｇａｌａｃｔｉａｅのようなグラム陽性細菌に対する免疫原性組成物
WO2006024020A2 (en) 2004-08-27 2006-03-02 Novartis Vaccines And Diagnostics Inc. Hcv non-structural protein mutants and uses thereof
US7381705B2 (en) * 2004-09-29 2008-06-03 The Administrators Of The Tulane Educational Fund Inhibitors of hepatitis C virus
WO2007031867A2 (en) 2005-05-25 2007-03-22 Tripep Ab A hepatitis c virus non-stru tural ns3/4a fusion gene
CN101641334B (zh) 2007-03-20 2012-02-15 泰尔茂株式会社 氧化显色化合物或其盐及其制备方法、以及试剂组合物及使用其的试验用具
EP2185195A2 (en) 2007-08-16 2010-05-19 Tripep Ab Immunogen platform
EP2244695A1 (en) 2007-12-07 2010-11-03 Novartis AG Compositions for inducing immune responses
WO2009130588A2 (en) 2008-04-22 2009-10-29 Tripep Ab Immunogen platform
WO2009143085A1 (en) 2008-05-19 2009-11-26 Anza Therapeutics, Inc. Compositions comprising prfa*mutant listeria and methods of use thereof
EP2405943A2 (en) 2009-03-09 2012-01-18 William Henry Hapten-carrier conjugates with bacterial toxins having a signal peptide as carrier and their use in immunogenic compositions
CA2766907A1 (en) 2009-07-06 2011-01-13 Novartis Ag Self replicating rna molecules and uses thereof
RU2625546C2 (ru) 2010-07-06 2017-07-14 Новартис Аг Катионные эмульсии "масло-в-воде"
CN103796639B (zh) 2011-07-06 2017-05-31 诺华股份有限公司 阳离子水包油乳液
JP6059220B2 (ja) 2011-07-06 2017-01-18 ノバルティス アーゲー 核酸を含む水中油型エマルジョン
JP6305925B2 (ja) 2011-10-11 2018-04-18 ノバルティス アーゲー 組換え自己複製ポリシストロニックｒｎａ分子
RU2667429C2 (ru) * 2013-05-10 2018-09-19 Соединенные Штаты Америки, В Лице Секретаря, Департамента Здравоохранения И Социального Обеспечения Сша Композиции и способы для одновременного обнаружения hcv антигена/антитела
RU2568872C1 (ru) * 2014-10-15 2015-11-20 Игорь Геннадьевич Сивов Лекарственное средство для лечения вирусного гепатита с
KR102268785B1 (ko) 2014-11-27 2021-06-25 킴벌리-클라크 월드와이드, 인크. 표면에서 노로바이러스를 검출하기 위한 장치 및 방법
CA2980718C (en) 2015-03-27 2021-06-01 Ortho-Clinical Diagnostics, Inc. Hcv ns4a/modified ns3 polypeptides and uses thereof
MA44723A (fr) 2016-04-18 2019-02-27 Celldex Therapeutics Inc Anticorps agonistes se liant au cd40 humain et leurs utilisations

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4542016A (en) * 1981-03-27 1985-09-17 Institut Merieux Non-a non-b hepatitis surface antigen useful for the preparation of vaccines and methods of use
US4702909A (en) * 1982-05-05 1987-10-27 Louisiana State University A & M Non-A, non-B hepatitis antigen, antigen compositions, vaccine and diagnostic reagent
US4870026A (en) * 1982-09-16 1989-09-26 The General Hospital Corporation Non-A, non-B. hepatitis, virus, methods of identification purification, characterization, diagnosis and immunization
US5032511A (en) * 1987-03-31 1991-07-16 Mitsubishi Kasei Corporation DNA fragments coding for antigens specific to non-A non-B hepatitis, expression vectors containing said DNA fragments, transformants and process for producing said antigens
CN1049686C (zh) * 1987-11-18 2000-02-23 希龙股份有限公司 非ａ和非ｂ肝炎病毒的诊断及疫苗
AU624105B2 (en) * 1987-11-18 1992-06-04 Novartis Vaccines And Diagnostics, Inc. Nanbv diagnostics and vaccines
AU3748489A (en) * 1988-06-17 1990-01-12 Genelabs Incorporated Enterically transmitted non-a/non-b hepatitis viral agent
AU4046489A (en) * 1988-07-06 1990-02-05 Genelabs Incorporated Post-transfusion, non-a, non-b hepatitis virus and antigens
JP2696116B2 (ja) * 1988-09-30 1998-01-14 財団法人阪大微生物病研究会 非ａ非ｂ肝炎患者の血清と抗原抗体反応するペプチド、及び該ペプチドをコードするｄｎａ
HU225068B1 (en) * 1989-03-17 2006-05-29 Chiron Corp Process for producing diagnostics and vaccine of nanbh

Also Published As

Publication number Publication date
JP2006169233A (ja) 2006-06-29
AU4750693A (en) 1993-12-16
FI905591A0 (fi) 1990-11-12
ATE286979T1 (de) 2005-01-15
JPH07145194A (ja) 1995-06-06
JP3171792B2 (ja) 2001-06-04
WO1990011089A1 (en) 1990-10-04
HU902814D0 (en) 1991-03-28
NO303941B1 (no) 1998-09-28
EP1394255A3 (en) 2004-06-02
ES2020152T3 (es) 2005-07-16
DE69034182T2 (de) 2005-12-15
KR0185373B1 (ko) 1999-05-01
JP2656995B2 (ja) 1997-09-24
JP2007254475A (ja) 2007-10-04
AU666767B2 (en) 1996-02-22
AU4750493A (en) 1994-01-20
JPH04504715A (ja) 1992-08-20
IE20060608A1 (en) 2006-09-20
KR920700045A (ko) 1992-02-19
JPH10309197A (ja) 1998-11-24
FI107610B (fi) 2001-09-14
JP2009292819A (ja) 2009-12-17
ES2228297T1 (es) 2005-04-16
IL93764A0 (en) 1990-12-23
CA2012482A1 (en) 1990-09-17
AU666576B2 (en) 1996-02-15
FI20002014A (fi) 2000-09-13
JP2000039434A (ja) 2000-02-08
DK0388232T3 (da) 2005-02-07
ES2020152A4 (es) 1991-08-01
JP2007332148A (ja) 2007-12-27
DE388232T1 (de) 1991-05-02
IL93764A (en) 2003-12-10
CA2012482C (en) 2004-11-23
KR0167125B1 (en) 1999-05-01
NO904712L (no) 1990-10-30
EP0388232B9 (en) 2005-10-26
AU640920B2 (en) 1993-09-09
EP1394255A2 (en) 2004-03-03
FI106211B (fi) 2000-12-15
JP2006111632A (ja) 2006-04-27
HU225068B1 (en) 2006-05-29
PT93480A (pt) 1990-11-07
JPH07101986A (ja) 1995-04-18
EP0388232B1 (en) 2005-01-12
GR910300016T1 (en) 1991-11-15
EP1034785A3 (en) 2004-06-02
JP2693908B2 (ja) 1997-12-24
FI20002013A (fi) 2000-09-13
DE69034182D1 (de) 2005-03-03
HU211981A9 (en) 1996-01-29
HUT54896A (en) 1991-04-29
JPH09215497A (ja) 1997-08-19
IE20060607A1 (en) 2006-09-20
PT93480B (pt) 1997-07-31
EP0388232A1 (en) 1990-09-19
JP2009275046A (ja) 2009-11-26
AU4750593A (en) 1993-12-16
ES2020152T4 (es) 2006-11-16
JPH10295389A (ja) 1998-11-10
MY110260A (en) 1998-03-31
DE03016585T1 (de) 2005-03-31
EP1034785A2 (en) 2000-09-13
UA50829C2 (uk) 2002-11-15
AU666766B2 (en) 1996-02-22
JP2809987B2 (ja) 1998-10-15
AU5278390A (en) 1990-10-22
FI107619B (fi) 2001-09-14

Similar Documents

Publication Publication Date Title
NO904712D0 (no) Nanbh diagnostiske midler og vaksiner.
Kumar et al. Hypervariable region of hepatitis C virus envelope glycoprotein (E2/NS1) in an agammaglobulinemic patient
YU48038B (sh) Postupak za dijagnostiku ne-a, ne-v hepatitisa
DE69334357D1 (de) Nachweis und Typisierung das Hepatitis C Virus (HCV) mittels 5'UTR und NS5 Nukleinsäuresequenzen
WO1994025601A3 (en) New sequences of hepatitis c virus genotypes and their use as therapeutic and diagnostic agents
WO1996013590A3 (en) New sequences of hepatitis c virus genotypes and their use as prophylactic, therapeutic and diagnostic agents
DK0585398T3 (da) HCV genomiske sekvenser til diagnostiske og terapeutiske midler
CA2389206A1 (en) Activation of hcv-specific t cells
DE69434116D1 (en) Hepatitis-c virus typ 4,5 und 6
KR870000426A (ko) 합성 fmdv 백신용 화합물의 제조방법
Katayama et al. Full-length GBV-C/HGV genomes from nine Japanese isolates: characterization by comparative analyses
Akkina Pestivirus bovine viral diarrhea virus polypeptides: identification of new precursor proteins and alternative cleavage pathways
KR900009979A (ko) 일본 뇌염 비루스 비구조 단백질의 제조방법
Kim et al. Genotype distribution and comparison of the putative envelope region of hepatitis C virus from Korean patients
IS3511A7 (is) Fjölpeptíð framleidd með aðferðum líftækninnar, kjarnsýrur sem samsvara þeim, og notkun fjölpeptíðanna sem bóluefnis gegn VHS veiru í fiski
JPS642586A (en) Western subtype dna and rna molecule of fsme-virus, polypeptide coded by the molecule and its usage
TH7280EX (th) เพปไทด์ที่เป็นแอนติเจนของไวรัสโรคตับอักเสบชนิดnon-A,non-B

Legal Events

Date Code Title Description
MK1K Patent expired